MicroRNA-205 Regulates HER3 in Human Breast Cancer
Overview
Authors
Affiliations
An increasing amount of experimental evidence shows that microRNAs can have a causal role in breast cancer tumorigenesis as a novel class of oncogenes or tumor suppressor genes, depending on the targets they regulate. HER2 overexpression is a hallmark of a particularly aggressive subset of breast tumors, and its activation is strictly dependent on the trans-interaction with other members of HER family; in particular, the activation of the PI3K/Akt survival pathway, so critically important in tumorigenesis, is predominantly driven through phosphorylation of the kinase-inactive member HER3. Here, we show that miR-205, down-modulated in breast tumors compared with normal breast tissue, directly targets HER3 receptor, and inhibits the activation of the downstream mediator Akt. The reintroduction of miR-205 in SKBr3 cells inhibits their clonogenic potential and increases the responsiveness to tyrosine-kinase inhibitors Gefitinib and Lapatinib, abrogating the HER3-mediated resistance and restoring a potent proapoptotic activity. Our data describe miR-205 as a new oncosuppressor gene in breast cancer, able to interfere with the proliferative pathway mediated by HER receptor family. Our study also provides experimental evidence suggesting that miR-205 can improve the responsiveness to specific anticancer therapies.
Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.
Benacka R, Szaboova D, Gulasova Z, Hertelyova Z Int J Mol Sci. 2025; 26(1.
PMID: 39795985 PMC: 11719911. DOI: 10.3390/ijms26010127.
Ouyang B, Bi M, Jadhao M, Bick G, Zhang X Cancers (Basel). 2024; 16(23.
PMID: 39682180 PMC: 11640040. DOI: 10.3390/cancers16233992.
Yasavoli-Sharahi H, Shahbazi R, Alsadi N, Robichaud S, Kambli D, Izadpanah A Cancer Med. 2024; 13(19):e70277.
PMID: 39382253 PMC: 11462599. DOI: 10.1002/cam4.70277.
HER3 receptor and its role in the therapeutic management of metastatic breast cancer.
Zhu M, Yu M, Meng Y, Yang J, Wang X, Li L J Transl Med. 2024; 22(1):665.
PMID: 39020378 PMC: 11253420. DOI: 10.1186/s12967-024-05445-8.
HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs.
Zeng H, Wang W, Zhang L, Lin Z Cancer Drug Resist. 2024; 7:14.
PMID: 38835349 PMC: 11149107. DOI: 10.20517/cdr.2024.11.